Koninklijke Philips NV

PHIA

Equity

ISIN NL0000009538 / Valor 1106818

Euronext - Euronext Amsterdam (2026-09-04)

EUR 22.35%

Koninklijke Philips NV
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Koninklijke Philips NV, commonly known as Philips, is a diversified technology company headquartered in the Netherlands. It operates globally, focusing on health technology and personal health products. Philips is renowned for its wide range of healthcare solutions, including diagnostic imaging, patient monitoring systems, and health informatics, as well as consumer health products like electric toothbrushes and sleep apnea devices. The company's business strategy is centered around leveraging innovative technology to improve people's health and well-being, aiming to provide integrated healthcare solutions that span the health continuum from healthy living and prevention, to diagnosis, treatment, and home care. Philips' executive committee, led by the CEO, plays a crucial role in steering the company's strategic direction, ensuring the deployment of its strategies and policies effectively to achieve its objectives and results. This structure supports Philips in its mission to make the world healthier and more sustainable through innovation.

Summarized from source with an LLMView SourceSector: Technology

Sales and orders

Comparable sales increased 4% across all segments. Comparable order intake declined 1% overall, with timing effects—certain large Connected Care orders shifted into Q3—while Europe saw strong double‑digit order growth.

Adjusted EBITA and tariff refund impact

Adjusted EBITA margin rose to 16.4% for the quarter, driven materially by a US tariff refund benefit of ~4.2%. Excluding that benefit, Adjusted EBITA was slightly down due to cost inflation and higher tariffs, partly offset by higher sales and productivity.

Segment performance

Diagnosis & Treatment: comparable sales +2%; Adjusted EBITA margin 13.9% (including ~4.6% US tariff refund); ex-refund margin declined mainly from cost inflation, tariffs and mix. Connected Care: comparable sales +2%; Adjusted EBITA margin 17.8% (including ~6.1% refund); ex-refund improvements from operations and productivity. Personal Health: comparable sales +8%; Adjusted EBITA margin 23.0% (including ~5.0% refund); ex-refund benefit from higher sales and productivity.

Productivity and cost management

Productivity and cost measures delivered EUR 132 million in savings in the quarter. Philips remains on track for EUR 1.5 billion of savings under its 2026–2028 productivity program, helping to offset inflation and tariff pressures.

Cash flow and balance sheet items

Net cash flows from operating activities were broadly flat: higher working capital outflows were largely offset by the US tariff refund received during the quarter.

Dividend and outlook

Philips completed the 2025 dividend distribution in Q2 2026 (EUR 0.85 per common share; 43.8% paid in cash). The company reiterated its full‑year 2026 outlook, which reflects currently known tariffs and excludes ongoing Philips Respironics‑related proceedings (including the US DOJ and State Attorneys General investigations).

Summarized from source with an LLMView Source

Key figures

-6.01%1Y

9.37%3Y

-41.9%5Y

Performance

27.3%1Y

32.7%3Y

35.1%5Y

Volatility